Solu Therapeutics

At Solu Therapeutics, we are advancing new approaches to drug discovery by combining the precision of small molecules with the versatility of antibodies. Our CyTAC™ platform is designed to engage tumor and immune cells across oncology, immunology, and inflammation, while our TicTAC™ platform explores long-acting antagonism and agonism for challenging targets. By linking selective small molecules to effector antibodies with our proprietary linker technology, we are enabling depletion of pathogenic cells through targeting of cell surface proteins not typically accessible with antibodies. Learn more about our platforms and pipeline: https://lnkd.in/dPDufvzg

The work doesn’t stop with the conclusion of #BloodCancerAwarenessMonth. We’re keeping the momentum going in October by sponsoring our third #LightTheNight event with our friends at Blood Cancer United. Light The Night is a special way to bring light to the darkness of cancer. We’ll join our community at Boston Common to raise valuable funds that directly support patients and families navigating their treatment journeys. Register for the Boston event on October 16: https://lnkd.in/dsJ9csEB

Today on #WorldCancerResearchDay, we reflect on the critical role of scientific discovery in transforming cancer care. Every breakthrough brings new therapies, better diagnostics, and hope to people living with cancer. For those facing cancers that are difficult to treat, there is still much work to be done. At Solu, we are driven by this challenge, advancing our CyTAC™ platform to explore new ways to tackle these difficult-to-treat cancers. We are proud to stand with the global cancer community, including patients, families, and researchers, as we push forward together. Learn more about our work in #oncology: https://lnkd.in/efAFUfRh

We’re proud to be part of Massachusetts’ vibrant life sciences community at Lilly Gateway Labs in the Eli Lilly and Company Seaport Innovation Center. This ecosystem of innovation gives us the opportunity to collaborate with leading researchers, access cutting-edge resources, and advance our mission to develop transformative medicines for patients. As we mark our first year in this space, we’re excited by the progress we’ve made in expanding our research capabilities, advancing our CyTAC™ and TicTAC™ programs, and building strong partnerships across the local life sciences network. Learn more about our space in this year’s BioSpace GeneTown feature: https://lnkd.in/e6D4VPvx

Chronic pain, in its many forms, affects millions of people around the world. During Pain Awareness Month, we recognize the profound physical, emotional, and social toll it takes on patients, families, and communities. Alongside our work in oncology, we are advancing several pain programs through our TicTAC™ platform. These include potential therapies designed to selectively target sodium ion channels, with one program focused on NaV1.7, another on NaV1.8, and a third aimed at dual inhibition of both. By pursuing multiple approaches, we are working to expand the possibilities for patients living with chronic pain. Learn about our TicTAC platform and other ongoing work on our website: https://lnkd.in/eGfmcc3Q

We’re advancing a new paradigm in drug discovery. Our CyTAC™ platform links selective small molecules to engineered antibodies, potentially creating therapies designed to target cell surface proteins that were previously out of reach. With this approach, we are tackling hematologic malignancies like CMML, as well as diseases in immunology and inflammation. These are areas where patients continue to face limited treatment options. In a recent interview with BioTuesdays, our CEO Phil Vickers highlighted our pipeline, experienced leadership team, and the promise of our platform to deliver new possibilities for patients: https://lnkd.in/g67xSH_q

Leukemia is a group of blood cancers that affect the bone marrow and blood, disrupting the normal production of healthy blood cells. While important advances have been made in some types of leukemia, patients with less common forms remain underserved. Chronic myelomonocytic leukemia (CMML) primarily affects older adults, and with few available treatment options, there is a critical need for new approaches. At Solu Therapeutics, our lead CyTAC™ program is currently being tested in CMML, with the potential to expand into acute myeloid leukemia (AML) and other blood cancers. We are advancing therapies that uniquely combine small molecules and antibodies to explore new possibilities for patients living with this challenging disease. Learn more: https://lnkd.in/efAFUfRh #BloodCancerAwarenessMonth #LeukemiaAwarenessMonth

At Solu Therapeutics, we recognize the strength of patients and families living with blood cancers and the urgency of advancing new treatment options for less common, underserved cancers that affect people worldwide. September is #BloodCancerAwarenessMonth, a reminder that treatment and support must reach every patient, family, and community at every stage of disease. For those with conditions like chronic myelomonocytic leukemia (CMML), options remain limited, and innovation is needed to change the standard of care. Together with our partners at Blood Cancer United (formerly known as LLS), we proudly stand with the blood cancer community in the fight for new, transformative treatments and better outcomes. Learn more about our work in #oncology: https://lnkd.in/efAFUfRh And head to their website for more resources: https://lnkd.in/gvcSZEpe

Our team wrapped up the summer season with a well-deserved outing right in our backyard, enjoying the beauty of the Boston Harbor! After a busy season of hard work and meaningful progress in the lab, it was great to unwind and celebrate together as we gear up for an exciting rest of the year.

Blood cancers, also known as hematologic malignancies, start in the bone marrow, blood, or lymphatic system. They include diseases like leukemia, lymphoma, multiple myeloma, and chronic myelomonocytic leukemia (CMML), an aggressive cancer that begins in the bone marrow. At Solu Therapeutics, CMML is a key area of focus. Despite its severity and poor survival rate, treatment options for CMML remain limited, and we’re working to change that. Our team is developing a novel therapeutic approach to CMML with the goal of bringing better options to patients and their families. Read more on our website: www.solutherapeutics.com